Rivanna Medical, Inc.

Rivanna Medical, based in Charlottesville, Virginia, specializes in advanced medical imaging technology, focusing on innovative solutions for neuraxial anesthesia procedures to enhance precision and improve patient outcomes. Founded in 2010 in Charlottesville, Virginia, Rivanna Medical develops technology for neuraxial anesthesia, specifically the Accuro Neuraxial Guidance System. In July 2025, Rivanna Medical, Inc. received approximately USD 9.

92 million in grant funding from returning investor Biomedical Advanced Research and Development Authority. The founders include Kevin Owen, and Will Mauldin, with Murillo Florêncio serving as CEO. Rivanna Medical has completed five since inception, reflecting its commitment to advancing medical imaging. Rivanna Medical specializes in advanced medical imaging technology, with a primary focus on its flagship product, the Accuro Neuraxial Guidance System.

This system employs AI-enabled image guidance and proprietary bone-imaging technology to automate landmark identification for neuraxial anesthesia procedures, including epidurals and spinal anesthesia. Accuro enhances the accuracy and efficiency of needle placements, particularly in patients with higher BMI, complex anatomy, or atypical spinal conditions. Launched in 2010, the system has demonstrated clinically proven improvements in first-attempt success rates. Rivanna Medical serves a diverse client base, including hospitals and anesthesia providers across the United States and internationally, emphasizing labor and delivery departments where over 3.

5 million neuraxial procedures are performed annually. Rivanna Medical generates revenue primarily from direct sales of its Accuro Neuraxial Guidance System, priced starting at USD 2,995, with no cloud subscription required. This sales strategy allows healthcare facilities to purchase the device outright. The company engages in partnerships with healthcare institutions to facilitate training and integration of their imaging technology into existing anesthesiology practices, enhancing user competence and patient outcomes.

The company aims to enhance its product line and expand into new markets, although specific regions or timelines for this expansion have not been disclosed. In August 2025, Rivanna Medical, Inc. raised USD 2. 4 million in grant and venture funding from Virginia Catalyst and other unspecified investors.

The company will use the August 2025 funding to accelerate the development and commercialization of its Accuro 3S diagnostic ultrasound system.